3501 related articles for article (PubMed ID: 18539916)
1. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
; Patel A; MacMahon S; Chalmers J; Neal B; Billot L; Woodward M; Marre M; Cooper M; Glasziou P; Grobbee D; Hamet P; Harrap S; Heller S; Liu L; Mancia G; Mogensen CE; Pan C; Poulter N; Rodgers A; Williams B; Bompoint S; de Galan BE; Joshi R; Travert F
N Engl J Med; 2008 Jun; 358(24):2560-72. PubMed ID: 18539916
[TBL] [Abstract][Full Text] [Related]
2. Glucose control and vascular complications in veterans with type 2 diabetes.
Duckworth W; Abraira C; Moritz T; Reda D; Emanuele N; Reaven PD; Zieve FJ; Marks J; Davis SN; Hayward R; Warren SR; Goldman S; McCarren M; Vitek ME; Henderson WG; Huang GD;
N Engl J Med; 2009 Jan; 360(2):129-39. PubMed ID: 19092145
[TBL] [Abstract][Full Text] [Related]
3. Effects of intensive glucose lowering in type 2 diabetes.
; Gerstein HC; Miller ME; Byington RP; Goff DC; Bigger JT; Buse JB; Cushman WC; Genuth S; Ismail-Beigi F; Grimm RH; Probstfield JL; Simons-Morton DG; Friedewald WT
N Engl J Med; 2008 Jun; 358(24):2545-59. PubMed ID: 18539917
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of intensive glucose lowering on cardiovascular outcomes.
; Gerstein HC; Miller ME; Genuth S; Ismail-Beigi F; Buse JB; Goff DC; Probstfield JL; Cushman WC; Ginsberg HN; Bigger JT; Grimm RH; Byington RP; Rosenberg YD; Friedewald WT
N Engl J Med; 2011 Mar; 364(9):818-28. PubMed ID: 21366473
[TBL] [Abstract][Full Text] [Related]
5. Severe hypoglycemia and risks of vascular events and death.
Zoungas S; Patel A; Chalmers J; de Galan BE; Li Q; Billot L; Woodward M; Ninomiya T; Neal B; MacMahon S; Grobbee DE; Kengne AP; Marre M; Heller S;
N Engl J Med; 2010 Oct; 363(15):1410-8. PubMed ID: 20925543
[TBL] [Abstract][Full Text] [Related]
6. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
Zoungas S; Chalmers J; Neal B; Billot L; Li Q; Hirakawa Y; Arima H; Monaghan H; Joshi R; Colagiuri S; Cooper ME; Glasziou P; Grobbee D; Hamet P; Harrap S; Heller S; Lisheng L; Mancia G; Marre M; Matthews DR; Mogensen CE; Perkovic V; Poulter N; Rodgers A; Williams B; MacMahon S; Patel A; Woodward M;
N Engl J Med; 2014 Oct; 371(15):1392-406. PubMed ID: 25234206
[TBL] [Abstract][Full Text] [Related]
7. Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-up.
Reaven PD; Emanuele NV; Wiitala WL; Bahn GD; Reda DJ; McCarren M; Duckworth WC; Hayward RA;
N Engl J Med; 2019 Jun; 380(23):2215-2224. PubMed ID: 31167051
[TBL] [Abstract][Full Text] [Related]
8. Glycaemic control and macrovascular and microvascular outcomes: A systematic review and meta-analysis of trials investigating intensive glucose-lowering strategies in people with type 2 diabetes.
Kunutsor SK; Balasubramanian VG; Zaccardi F; Gillies CL; Aroda VR; Seidu S; Khunti K
Diabetes Obes Metab; 2024 Jun; 26(6):2069-2081. PubMed ID: 38409644
[TBL] [Abstract][Full Text] [Related]
9. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes.
Hayward RA; Reaven PD; Wiitala WL; Bahn GD; Reda DJ; Ge L; McCarren M; Duckworth WC; Emanuele NV;
N Engl J Med; 2015 Jun; 372(23):2197-206. PubMed ID: 26039600
[TBL] [Abstract][Full Text] [Related]
10. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.
Ismail-Beigi F; Craven T; Banerji MA; Basile J; Calles J; Cohen RM; Cuddihy R; Cushman WC; Genuth S; Grimm RH; Hamilton BP; Hoogwerf B; Karl D; Katz L; Krikorian A; O'Connor P; Pop-Busui R; Schubart U; Simmons D; Taylor H; Thomas A; Weiss D; Hramiak I;
Lancet; 2010 Aug; 376(9739):419-30. PubMed ID: 20594588
[TBL] [Abstract][Full Text] [Related]
11. Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial.
Woodward M; Patel A; Zoungas S; Liu L; Pan C; Poulter N; Januszewicz A; Tandon N; Joshi P; Heller S; Neal B; Chalmers J
Diabetes Care; 2011 Dec; 34(12):2491-5. PubMed ID: 21972410
[TBL] [Abstract][Full Text] [Related]
12. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation.
J Hypertens Suppl; 2001 Nov; 19(4):S21-8. PubMed ID: 11848259
[TBL] [Abstract][Full Text] [Related]
14. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
Zoungas S; de Galan BE; Ninomiya T; Grobbee D; Hamet P; Heller S; MacMahon S; Marre M; Neal B; Patel A; Woodward M; Chalmers J; ; Cass A; Glasziou P; Harrap S; Lisheng L; Mancia G; Pillai A; Poulter N; Perkovic V; Travert F
Diabetes Care; 2009 Nov; 32(11):2068-74. PubMed ID: 19651921
[TBL] [Abstract][Full Text] [Related]
15. Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
Tian J; Ohkuma T; Cooper M; Harrap S; Mancia G; Poulter N; Wang JG; Zoungas S; Woodward M; Chalmers J
Diabetes Care; 2020 Jun; 43(6):1293-1299. PubMed ID: 32193249
[TBL] [Abstract][Full Text] [Related]
16. 10-year follow-up of intensive glucose control in type 2 diabetes.
Holman RR; Paul SK; Bethel MA; Matthews DR; Neil HA
N Engl J Med; 2008 Oct; 359(15):1577-89. PubMed ID: 18784090
[TBL] [Abstract][Full Text] [Related]
17. Relationship of glycaemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin.
Freemantle N; Danchin N; Calvi-Gries F; Vincent M; Home PD
Diabetes Obes Metab; 2016 Feb; 18(2):152-8. PubMed ID: 26511332
[TBL] [Abstract][Full Text] [Related]
18. Basal insulin and cardiovascular and other outcomes in dysglycemia.
; Gerstein HC; Bosch J; Dagenais GR; Díaz R; Jung H; Maggioni AP; Pogue J; Probstfield J; Ramachandran A; Riddle MC; Rydén LE; Yusuf S
N Engl J Med; 2012 Jul; 367(4):319-28. PubMed ID: 22686416
[TBL] [Abstract][Full Text] [Related]
19. Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
van der Leeuw J; Visseren FL; Woodward M; van der Graaf Y; Grobbee DE; Harrap S; Heller S; Mancia G; Marre M; Poulter N; Zoungas S; Chalmers J
Diabetologia; 2016 Dec; 59(12):2603-2612. PubMed ID: 27586250
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
Zinman B; Ahrén B; Neubacher D; Patel S; Woerle HJ; Johansen OE
Can J Diabetes; 2016 Feb; 40(1):50-7. PubMed ID: 26474870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
